Audited financial statements 2016
Kedrion’s shareholders meeting approved the 2016 stand-alone Financial Statements and acknowledged the 2016 Consolidated FS
Annual Results 2016
Consolidated turnover of 659.3 million Euro, a growth of 89 million Euro or 15.6%
Kedrion Biopharma strengthens its position on the US market
Granted exclusive rights to commercialize a lifesaving drug in the US
Kedrion Notes 2019 Tender Offer results
Kedrion has decided to accept for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000
Cash Tender Offer for Notes due 24 April 2019
Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019.
Kedrion receives the “VedoGreen, Green Excellence in Innovation” Award
The awards ceremony held in Milan on November 17, during Waiting for Expo 2015, Green Economy 2.0
Kedrion joins the programme “ELITE for Large Corporates”
Launched by Borsa Italiana, ELITE is targeted to companies aiming at strengthening their global leadership
New generation immunoglobulins: in January production of clinical batches
The first batch for the feasibility test was produced at the Gödöllő plant in September with results in compliance with specifications
Kedrion’s key financials and milestones in the new Investor Relations area
Website area dedicated to providing the financial community with latest information regarding the Kedrion Bond
Bond marked by Wide Distribution
The success of the operation is reflected in the wide variety of investors involved